Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- An Overview of Metabolic Syndrome
- Disease Defi nition
- Prevalence
- Is Metabolic Syndrome a Discrete Disease?
- Perspective of Regulatory Agencies
- Perspective of Payers
- Current Treatment Options
- FDCs to Treat Dyslipidemia/Hypertension (Pfi zer' s Caduet)
- Agents to Treat Obesity
- Agents to Treat Diabetes
- Strategies for Developing Agents for Metabolic Syndrome
- Multimodal Approaches
- Peroxisome Proliferator-Activated Receptor Agonists
- Cortisol Modulators
- Fixed-Dose Combinations
- What Is the Future for Metabolic Syndrome Treatment?
Tables
- 1. Defi nitions for Metabolic Syndrome
- 2. Prevalent Cases of Metabolic Syndrome, 2006
- 3. Metabolic Syndrome: Current Therapies and 2006 Worldwide Sales
- 4. Agents in Development to Treat Multiple Components of Metabolic Syndrome
- 5. Agents in Development to Treat Single Components of Metabolic Syndrome
Figures
- 1. Prevalent Cases of Metabolic Syndrome and Component Diseases in the
Seven Major Markets, 2006
- 2. Prescriptions Attributed to Metabolic Syndrome in the United States,
2000-2006
- 3. Disease Targets of Multimodal and Fixed-Dose Combination Agents for
Metabolic Syndrome Components
|
Related Report
|
View Cart
